Studies on Combination of Platinum Drugs Cisplatin and Oxaliplatin with Phytochemicals Anethole and Curcumin in Ovarian Tumour Models

被引:0
|
作者
Nessa, Meher U.
Beale, Philip [2 ]
Chan, Charles [3 ]
Yu, Jun Q.
Huq, Fazlul [1 ]
机构
[1] Univ Sydney, Discipline Biomed Sci, Sch Med Sci, Sydney Med Sch, Lidcombe, NSW 1825, Australia
[2] Concord Hosp, Sydney Canc Ctr, Concord, NSW, Australia
[3] Concord Hosp, Dept Pathol, Concord, NSW, Australia
关键词
Drug resistance; drug combination; anethole; curcumin; cisplatin; oxaliplatin; NF-KAPPA-B; INDUCED APOPTOSIS; GENE-EXPRESSION; CANCER CELLS; SYNERGISM; INHIBITION; ACTIVATION; CARCINOMA; PATHWAYS; SURVIVAL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemopreventative phytochemicals having antitumour and antioxidant properties can overcome problems of chemoresistance and nonspecific toxicity towards normal cells that are associated with platinum-based chemotherapy against cancer. These agents exert their effects by bringing into play numerous cellular proteins that in turn affect multiple steps in pathways leading to tumourigenesis. In this study, combinations of two cytotoxic phytochemicals anethole and curcumin were applied in binary combination with platinum drugs cisplatin and oxaliplatin to three epithelial ovarian cancer cell lines: A2780 (parent), A2780(cisR) (cisplatin-resistant) and A2780(ZD0473R) (ZD0473-resistant). Cell viability was quantified using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction assay and the combined drug action was analyzed based on the equations derived by Chou and Talalay (1984). Greatest synergism was observed when the phytochemical was added first followed by the platinum drug 2 h later and additiveness to antagonism in combined drug action was observed when the two compounds were administered as a bolus. If confirmed in vivo, the appropriate sequenced combinations of platinum with the phytochemicals may provide a means of overcoming drug resistance.
引用
收藏
页码:4843 / 4850
页数:8
相关论文
共 50 条
  • [31] A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
    Viens, P
    Petit, T
    Yovine, A
    Bougnoux, P
    Deplanque, G
    Cottu, PH
    Delva, R
    Lotz, JP
    Belle, SV
    Extra, JM
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 429 - 436
  • [32] A comparative efficacy study of Saquinavir in combination with cisplatin or paclitaxel in platinum-resistant ovarian cancer cells
    Waite, Terry-Ann E.
    Reboe, Monique
    Levy, Arkene
    Dhandayuthapani, Sivanesan
    Rathinavelu, Appu
    CANCER RESEARCH, 2015, 75
  • [33] Combination effects of platinum drugs and N 1, N 11 diethylnorspermine on spermidine/spermine N 1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants
    Tummala, Ramakumar
    Diegelman, Paula
    Hector, Suzanne
    Kramer, Debora L.
    Clark, Kimberly
    Zagst, Patricia
    Fetterly, Gerald
    Porter, Carl W.
    Pendyala, Lakshmi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 401 - 414
  • [34] Feasibility trial of paclitaxel (PXL), oxaliplatin (L-OHP) and cisplatin (CDDP) combination in advanced ovarian cancer patients
    Chouaki, N
    Taamma, A
    Ladem, A
    Delaloge, S
    Misset, JL
    Pautier, P
    Lhomme, C
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 1998, 9 : 72 - 72
  • [35] Preliminary results of whole-body hyperthermia in combination with oxaliplatin in patients with platinum-resistant/refractory ovarian cancer
    Siarheyeva, V.
    Petrovitch, S.
    Zhavrid, E.
    Istomin, Y. U.
    Baranau, Y.
    Mazurenko, A.
    Alexandrova, E.
    Zhuravkin, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 461 - 462
  • [36] Paclitaxel (PXL)-oxaliplatin (L-OHP) combination in patients with platinum-pretreated recurrent ovarian carcinoma (PPROC)
    Faivre, S
    Kalla, S
    Bensmaine, MA
    Bourdon, O
    Hauteville, D
    Extra, JM
    Cvitkovic, E
    Marty, M
    ANNALS OF ONCOLOGY, 1998, 9 : 96 - 97
  • [37] Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models
    Hall, MD
    Martin, C
    Ferguson, DJP
    Phillips, RM
    Hambley, TW
    Callaghan, R
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (01) : 17 - 30
  • [38] Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
    Sheng, W. J.
    Jiang, H.
    Wu, D. L.
    Zheng, J. H.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2013, 46 (08) : 650 - 658
  • [39] Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
    P Oliva
    A Decio
    V Castiglioni
    A Bassi
    E Pesenti
    M Cesca
    E Scanziani
    D Belotti
    R Giavazzi
    British Journal of Cancer, 2012, 107 : 360 - 369
  • [40] Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
    Oliva, P.
    Decio, A.
    Castiglioni, V.
    Bassi, A.
    Pesenti, E.
    Cesca, M.
    Scanziani, E.
    Belotti, D.
    Giavazzi, R.
    BRITISH JOURNAL OF CANCER, 2012, 107 (02) : 360 - 369